Objective To improve the diagnostic accuracy of non-puerperal breast abscess.Methods The mammographic findings of non-puerperal breast abscess in 10 cases were retrospectively reviewed and analyzed.Results The following X-ray signs of this disease were found on mammograms:(1)acute abscess:it showed irregular compact lesions with unclear boundary and no any structures in centre of lesion(5 cases),or mass lesion with hyper density and blurred boundary(1 case),skin edema (3 cases).(2)chronic abscess:it showed round or roundlike mass with sharp and clear boundary(2 cases),irregular long or short burr around the mass (2 cases),subabcesses(2 cases),skin thicken(2 cases) fistula (1 case).Conclusion The accuracy of diagnosing non-puerperal breast abscess can be improved by the combination of X-ray signs and clinical information.

ObjectiveTo research the intestinal absorption characteristics in rats of multiple constituents,when Wuwei-Jiangya recipe was used in rats and showed reducing blood pressure effects.Methods ① After extracting Wuwei-Jiangya recipe,we fed it to rats once daily,until the blood pressure reduced; ②Establish Wuwei-Jiangya recipe and intestinal absorption of multiple constituents fingerprint by using reverted gut sac method and RP-HPLC fmgerprint.ResultsAfter one week's administration,there was the hypotensive effects and multiple constituents can be absorbed by intestine.ConclusionWhen the drug works,reverted gut sac method for studying intestinal absorption constituents can be used for locking the exposure constituents.

OBJECTIVETo investigate the changes in the number and distribution of myoepithelial cells during atrophy of the rat parotid gland.

METHODSAtrophy of the right parotid was induced by ligating the right stensen duct of rats, histological changes of parotid glands were examined by hematoxylin-eosin (HE) staining during each step of glandular atrophy at the time of 0 (control), 1, 3, 5, 7, 14, 21, 30, 60, 100, and 150 days after ligation. Immunohistochemical labelling was performed to study the changes in number and distribution of myoepithelial cells during atrophy of the rat parotid gland.

RESULTSHistological analysis showed disappearance of the acini at 5 d and gradual decrease and fibrosis of the glandular lobules accompanied by the occurrence of duct-like structures. Quantitative analysis of myoepithelial cells showed significant increase in number up to day 5 after ligation, then followed by gradual increases at a low level, at last it was followed by a rapid decrease after the total number reached the peak in 100 days. In addition, the acini and intercalated ducts were covered by myoepithelial cells ranged from the shape of spindle to stellate during the early phase of atrophy, while spindle-shaped myoepithelial cells were located at the periphery of duct-like structures in the later phase of atrophy.

CONCLUSIONMyoepithelial cells proliferated rapidly up to day 5 after ligation, then followed by gradual increase at a low level, at last it was followed by a rapid decrease after the total number reached the peak in 100 days.

Actins ; Animals ; Atrophy ; Epithelial Cells ; Ligation ; Parotid Gland ; Rats ; Regeneration ; Salivary Ducts

Objective:To evaluate the 3-year survival outcomes and late injury between the self-designed patent single-channel applicator, which was modified from the traditional tandem applicator and wrapped with a oval-shield alloy around the source channel and standard Fletcher-type applicator in the high-dose-rate brachytherapy for cervical cancer.Methods:Patients initially diagnosed with cervical cancer in the Affiliated Hospital of Southwest Medical University from December 2011 to April 2017 were enrolled and randomly assigned into the external beam radiotherapy (EBRT)+ single-channel intracavitary applicator group (the patent single-channel group) and EBRT+ the Fletcher applicator group. The whole pelvis irradiation was delivered with 6-MV photons via a four-field box variant or anterior and posterior parallel fields. Five to six fractions of intracavitary brachytherapy were performed at a dose of 7 Gy at point A once a week after 30 Gy (Equivalent Dose in 2 Gy at point A: 80-90 Gy). Chemotherapy was given with intravenous injection of cisplatin at a dose of 40 mg/m 2 once weekly during EBRT. Clinical efficacy and safety were evaluated after corresponding treatment. Results:In total, 150 eligible cases were assigned into the Fletcher applicator group and 149 cases into the patent single-channel group. Up to December 2020, all patients had been followed up for 3 years, and the median duration of follow-up was 61 months. In the Fletcher group, the 3-year overall survival, progression-free survival and locoregional failure-free survival was 76.3%, 78.1% and 75.4%, and 83.8%, 80.3% and 85.5% in the single-channel group, respectively. In the Fletcher group, the cumulative rate of grade 3-4 late rectal complications was 3.3% and 6.7% in the single-channel group ( P=0.122). The cumulative rate of grade 3-4 bladder complications was 1.3% in the Fletcher group and 0.7% in the single-channel group ( P=1.000). Conclusion:The self-designed patent single-channel intracavitary applicator yields equivalent long-term clinical efficacy and safety to the standard Fletcher-type three-channel applicator in the HDR brachytherapy for uterine cervical cancer.

Objective: To evaluate whether the self-designed single-channel intracavitary applicator yields equivalent clinical efficacy and safety to the standard Fletcher-type three-channel applicator in the high-dose-rate (HDR) brachytherapy for uterine cervical cancer. Methods: From December 2011 to April 2017, patients initially diagnosed with cervical cancer were randomly assigned into the external beam radiotherapy (EBRT)+ single-channel intracavitary applicator group (the patent single-channel group) and EBRT+ the Fletcher applicator group. Whole pelvis irradiation was delivered with 6-MV photons via a four-field box variant or anterior and posterior parallel fields. Five to six fractions of intracavitary brachytherapy were performed at a dose of 7 Gy at point A once a week after 30 Gy (BED at point A: 80-90 Gy). Chemotherapy was given with intravenous injection of cisplatin at a dose of 40 mg/m² once weekly during EBRT.Clinical efficacy and safety were evaluated after the treatment. Results: In total, 150 eligible cases were assigned into the Fletcher applicator group and 149 cases into the patent single-channel group. The short-term clinical efficacy and acute toxicity did not significantly differ between two groups. The response rate was 94.0% in the Fletcher group, and 94.7% in the patent single-channel group. In the Fletcher applicator group, 76(50.7%) patients developed ≥ grade 3 hematologic toxicity and 61(40.9%) in the patent group (P=0.195). Conclusions: The self-designed patent single-channel intracavitary applicator yields equivalent clinical efficacy and safety (acute toxicity) to the standard Fletcher-type three-channel applicator in the HDR brachytherapy for uterine cervical cancer. Clincal Trial Registration Chinese Clinical Trial Registry (ChiCTR-TRC-12002321).